Comprehensive Stock Comparison
Compare DocGo Inc. (DCGO) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | FMS | 1.5% revenue growth vs DCGO's -1.2% |
| Value | DCGO | Lower P/E (4.0x vs 9.9x) |
| Quality / Margins | FMS | 5.0% net margin vs DCGO's -14.0% |
| Stability / Safety | FMS | Beta 0.40 vs DCGO's 1.20 |
| Dividends | DCGO | 100.0% yield; 1-year raise streak; FMS pays no meaningful dividend |
| Momentum (1Y) | FMS | +0.2% vs DCGO's -76.8% |
| Efficiency (ROA) | FMS | 3.2% ROA vs DCGO's -14.6%, ROIC 5.6% vs 7.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
DocGo is a mobile healthcare and medical transportation provider that brings medical services directly to patients' homes, workplaces, and events. It generates revenue primarily through contracted mobile health services—including COVID-19 testing and on-site event healthcare—and medical transportation services like ambulance and wheelchair transport. The company's competitive advantage lies in its integrated platform that combines transportation with on-site medical care, creating a seamless mobile healthcare delivery system.
Fresenius Medical Care is a global leader in dialysis care and products for patients with chronic kidney failure. It generates revenue through two main segments: dialysis services (about 75% of revenue) from its network of outpatient clinics and hospital contracts, and dialysis products (about 25%) including machines, dialyzers, and related supplies. The company's key advantage is its vertically integrated model—combining clinics, products, and services—which creates patient stickiness and economies of scale in the capital-intensive dialysis industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
FMS leads in 4 of 6 categories (Financial Metrics, Total Returns). DCGO leads in 2 (Valuation Metrics, Profitability & Efficiency).
Financial Metrics (TTM)
FMS is the larger business by revenue, generating $19.6B annually — 53.3x DCGO's $368M. FMS is the more profitable business, keeping 5.0% of every revenue dollar as net income compared to DCGO's -14.0%. On growth, FMS holds the edge at -0.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| RevenueTrailing 12 months | $368M | $19.6B |
| EBITDAEarnings before interest/tax | -$66M | $3.3B |
| Net IncomeAfter-tax profit | -$52M | $978M |
| Free Cash FlowCash after capex | $52M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +31.2% | +25.6% |
| Operating MarginEBIT ÷ Revenue | -22.0% | +9.3% |
| Net MarginNet income ÷ Revenue | -14.0% | +5.0% |
| FCF MarginFCF ÷ Revenue | +14.1% | +6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -48.9% | -0.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.4% | +8.5% |
Valuation Metrics
At 4.0x trailing earnings, DCGO trades at a 66% valuation discount to FMS's 11.8x P/E. On an enterprise value basis, DCGO's 0.9x EV/EBITDA is more attractive than FMS's 6.3x.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| Market CapShares × price | $73M | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $41M | $24.4B |
| Trailing P/EPrice ÷ TTM EPS | 3.99x | 11.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.89x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.32x |
| EV / EBITDAEnterprise value multiple | 0.92x | 6.33x |
| Price / SalesMarket cap ÷ Revenue | 0.12x | 0.59x |
| Price / BookPrice ÷ Book value/share | 0.25x | 0.81x |
| Price / FCFMarket cap ÷ FCF | 1.13x | — |
Profitability & Efficiency
FMS delivers a 6.8% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-20 for DCGO. DCGO carries lower financial leverage with a 0.18x debt-to-equity ratio, signaling a more conservative balance sheet compared to FMS's 0.76x. On the Piotroski fundamental quality scale (0–9), DCGO scores 7/9 vs FMS's 5/9, reflecting strong financial health.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| ROE (TTM)Return on equity | -19.8% | +6.8% |
| ROA (TTM)Return on assets | -14.6% | +3.2% |
| ROICReturn on invested capital | +7.5% | +5.6% |
| ROCEReturn on capital employed | +8.8% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.18x | 0.76x |
| Net DebtTotal debt minus cash | -$32M | $9.2B |
| Cash & Equiv.Liquid assets | $89M | $1.6B |
| Total DebtShort + long-term debt | $57M | $10.8B |
| Interest CoverageEBIT ÷ Interest expense | -38.97x | 6.84x |
Total Returns (with DRIP)
A $10,000 investment in FMS five years ago would be worth $7,718 today (with dividends reinvested), compared to $707 for DCGO. Over the past 12 months, FMS leads with a +0.2% total return vs DCGO's -76.8%. The 3-year compound annual growth rate (CAGR) favors FMS at 9.1% vs DCGO's -57.2% — a key indicator of consistent wealth creation.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | -0.2% |
| 1-Year ReturnPast 12 months | -76.8% | +0.2% |
| 3-Year ReturnCumulative with dividends | -92.2% | +29.7% |
| 5-Year ReturnCumulative with dividends | -92.9% | -22.8% |
| 10-Year ReturnCumulative with dividends | -93.0% | -28.5% |
| CAGR (3Y)Annualised 3-year return | -57.2% | +9.1% |
Risk & Volatility
FMS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than DCGO's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FMS currently trades 77.0% from its 52-week high vs DCGO's 22.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 0.40x |
| 52-Week HighHighest price in past year | $3.18 | $30.46 |
| 52-Week LowLowest price in past year | $0.66 | $20.95 |
| % of 52W HighCurrent price vs 52-week peak | +22.6% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 40.1 | 49.0 |
| Avg Volume (50D)Average daily shares traded | 624K | 518K |
Analyst Outlook
DCGO is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | DCGODocGo Inc. | FMSFresenius Medical… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $28.00 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | 3 |
| Dividend / ShareAnnual DPS | $11829.54 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +18.8% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Feb 26 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | 100 | 7.54 | -92.5% |
| Fresenius Medical C… (FMS) | 100 | 53.11 | -46.9% |
Fresenius Medical C… (FMS) returned -23% over 5 years vs DocGo Inc. (DCGO)'s -93%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | $48M | $617M | +1176.5% |
| Fresenius Medical C… (FMS) | $17.0B | $19.6B | +15.3% |
Fresenius Medical Care AG & Co. KGaA's revenue grew from $17.0B (2016) to $19.6B (2025) — a 1.6% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | -41.8% | 3.2% | +107.7% |
| Fresenius Medical C… (FMS) | 6.9% | 5.0% | -28.2% |
Fresenius Medical Care AG & Co. KGaA's net margin went from 7% (2016) to 5% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | 37.4 | 23.6 | -36.9% |
| Fresenius Medical C… (FMS) | 25.3 | 14.2 | -43.9% |
DocGo Inc. has traded in a 21x–86x P/E range over 4 years; current trailing P/E is ~4x. Fresenius Medical Care AG & Co. KGaA has traded in a 10x–39x P/E range over 9 years; current trailing P/E is ~12x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | -0.2 | 0.18 | +190.0% |
| Fresenius Medical C… (FMS) | 1.87 | 1.68 | -10.2% |
Fresenius Medical Care AG & Co. KGaA's EPS grew from $1.87 (2016) to $1.68 (2025) — a -1% CAGR.
Chart 6Free Cash Flow — 5 Years
DocGo Inc. generated $65M FCF in 2024 (+850% vs 2021). Fresenius Medical Care AG & Co. KGaA generated $0M FCF in 2025 (-100% vs 2021).
DCGO vs FMS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DCGO or FMS a better buy right now?
DocGo Inc. (DCGO) offers the better valuation at 4.0x trailing P/E, making it the more compelling value choice. Analysts rate Fresenius Medical Care AG & Co. KGaA (FMS) a "Hold" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DCGO or FMS?
On trailing P/E, DocGo Inc. (DCGO) is the cheapest at 4.0x versus Fresenius Medical Care AG & Co. KGaA at 11.8x.
03Which is the better long-term investment — DCGO or FMS?
Over the past 5 years, Fresenius Medical Care AG & Co. KGaA (FMS) delivered a total return of -22.8%, compared to -92.9% for DocGo Inc. (DCGO). A $10,000 investment in FMS five years ago would be worth approximately $8K today (assuming dividends reinvested). Over 10 years, the gap is even starker: FMS returned -28.5% versus DCGO's -93.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DCGO or FMS?
By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus DocGo Inc.'s 1.20β — meaning DCGO is approximately 201% more volatile than FMS relative to the S&P 500. On balance sheet safety, DocGo Inc. (DCGO) carries a lower debt/equity ratio of 18% versus 76% for Fresenius Medical Care AG & Co. KGaA — giving it more financial flexibility in a downturn.
05Which has better profit margins — DCGO or FMS?
Fresenius Medical Care AG & Co. KGaA (FMS) is the more profitable company, earning 5.0% net margin versus 3.2% for DocGo Inc. — meaning it keeps 5.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FMS leads at 9.3% versus 4.7% for DCGO. At the gross margin level — before operating expenses — DCGO leads at 34.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DCGO or FMS?
In this comparison, DCGO (100.0% yield) pays a dividend. FMS does not pay a meaningful dividend and should not be held primarily for income.
07Is DCGO or FMS better for a retirement portfolio?
For long-horizon retirement investors, Fresenius Medical Care AG & Co. KGaA (FMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (FMS: -28.5%, DCGO: -93.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DCGO and FMS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. DCGO pays a dividend while FMS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.